12 completed, 2 terminated, 2 unknown, 2 withdrawn. 21 Phase 1, 8 Phase 2.
Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis | Phase 1 | Completed | AQILION AB | 9 | 2025-06-13 | 2026-06-01 |
| Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma Lipopolysaccharides - Asthma; Eosinophilic, Asthma | Phase 1 | Not yet recruiting | National Jewish Health | 60 | 2024-04-01 | 2024-02-21 |
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). EP-104GI, Matching vehicle control - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Recruiting | Eupraxia Pharmaceuticals Inc. | 117 | 2023-03-31 | 2026-11-17 |
| SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects AQ280, Placebo - Eosinophilic Esophagitis (EoE) | Phase 1 | Completed | AQILION AB | 66 | 2022-07-20 | 2024-12-24 |
| A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab Cendakimab, CYP substrates - Eosinophilic Esophagitis | Phase 1 | Completed | Celgene | 16 | 2022-06-07 | 2024-12-20 |
| Targeted Elimination Diet in EoE Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy personalized exclusion diet based on CLE, empiric exclusion diet - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Unknown | Universitaire Ziekenhuizen KU Leuven | 25 | 2022-02-16 | 2024-06-27 |
| Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis BT-11 low, BT-11 high, Placebo - Eosinophilic Esophagitis | Phase 1 | Withdrawn | NImmune Biopharma | 2022-01-30 | 2023-06-07 | |
| A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma 610 30mg group, 610 100mg group, 610 300mg group - Asthma | Phase 1 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 24 | 2021-12-06 | 2022-10-18 |
| Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis CALY-002, Placebo - Eosinophilic Esophagitis, Celiac Disease | Phase 1 | Completed | Calypso Biotech BV | 73 | 2020-09-28 | 2024-04-09 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Sirolimus for Eosinophil-Associated Gastrointestinal Disorders sirolimus - Eosinophilic Gastroenteritis, Eosinophilic Esophagitis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 4 | 2013-03-07 | 2018-07-05 |
| Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Absorbable sugars - Eosinophilic Esophagitis | Phase 1 | Completed | Mayo Clinic | 20 | 2012-08-01 | 2014-06-24 |
| Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis dexlansoprazole - Gastroesophageal Reflux Disease, Eosinophilic Esophagitis | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2012-03-01 | 2012-04-19 | |
| Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis EUR-1100, placebo - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Completed | Forest Laboratories | 24 | 2011-09-01 | 2012-11-02 |
| Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/GleevecĀ® Indicated Hematological Disorders. Gleevec/Glivec - Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Phase 1 | Terminated | Novartis Pharmaceuticals | 3 | 2010-10-01 | 2012-03-13 |
| A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis Beclomethasone dipropionate, placebo - Eosinophilic Esophagitis | Phase 1 | Completed | Penn State University | 20 | 2010-03-01 | 2012-11-30 |
| Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Omalizumab - Eosinophilic Esophagitis | Phase 1 | Completed | O & O Alpan LLC | 19 | 2009-06-01 | 2012-03-14 |
| Trial of Montelukast in Eosinophilic Esophagitis Montelukast/ Singulair, Placebo - Eosinophilic Esophagitis | Phase 1 | Completed | Mayo Clinic | 41 | 2007-08-01 | 2015-11-03 |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Nilotinib - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 507 | 2005-04-01 | 2021-06-29 |
Showing 20 of 21. Sign in to see all of them.
Eosinophilic Esophagitis (15) · Hypereosinophilic Syndrome (4) · Pulmonary Eosinophilia (3) · Asthma (2) · Eosinophilic enteropathy (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Celiac Disease (1) · Churg-Strauss Syndrome (1) · Deglutition Disorders (1) · Esophagitis (1) · Food Hypersensitivity (1) · Gastroesophageal Reflux (1)
Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Leukocyte Disorders (21) · Immune System Diseases (19) · Hypersensitivity (17) · Hypersensitivity, Immediate (17) · Digestive System Diseases (15) · Esophageal Diseases (15) · Gastroenteritis (15) · Gastrointestinal Diseases (15) · Esophagitis (14) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3)
Azacitidine (1) · Beclomethasone (1) · Dexlansoprazole (1) · Endotoxins (1) · Imatinib Mesylate (1) · Lipopolysaccharides (1) · Omalizumab (1) · Population Groups (1) · Sirolimus (1) · Suspensions (1) · cendakimab (1) · heat-labile enterotoxin, E coli (1) · mepolizumab (1) · montelukast (1) · nilotinib (1)
Mayo Clinic (3) · AQILION AB (2) · Novartis Pharmaceuticals (2) · Advagene Biopharma Co. Ltd. (1) · Calypso Biotech BV (1) · Celgene (1) · Children's Hospital Medical Center, Cincinnati (1) · Eupraxia Pharmaceuticals Inc. (1) · Forest Laboratories (1) · M.D. Anderson Cancer Center (1) · NImmune Biopharma (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Jewish Health (1) · O & O Alpan LLC (1) · Penn State University (1)
United States (12) · Belgium (3) · Netherlands (3) · United Kingdom (3) · Australia (2) · Canada (2) · Finland (2) · Germany (2) · New Zealand (2) · Norway (2) · Switzerland (2) · Taiwan (2) · Austria (1) · China (1) · Denmark (1)
Calman P Prussin, M.D. (1) · David Katzka, MD (1) · Han-Pin Kuo, MD. Ph.D. (1) · Ikuo Hirano, MD (1) · Jeffrey A Alexander, MD (1) · Jeffrey A. Alexander, M.D. (1) · Jeymi Tambiah, MD (1) · Marc E. Rothenberg, MD (1) · Min Zhang, MD (1) · Nicholas Short (1)
PMID 16775235, PMID 17715389, PMID 21098399, PMID 23547655, PMID 24057647, PMID 25789989, PMID 26002753, PMID 27650328, PMID 30476587, PMID 37422688, PMID 41039829